Kiniksa Pharmaceuticals International, plc (KNSA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300M 600M 900M Q1 '22: 70.7M Q2 '22: 90M Q3 '22: 177M Q4 '22: 220.2M Q1 '23: 236.3M Q2 '23: 280.8M Q3 '23: 248.7M Q4 '23: 270.3M Q1 '24: 301.8M Q2 '24: 338.9M Q3 '24: 384.1M Q4 '24: 423.2M Q1 '25: 481.2M Q2 '25: 529.3M Q3 '25: 598M Q4 '25: 677.6M Q1 '26: 754M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit TTM

0 250M 500M 750M Q1 '22: 57.4M Q2 '22: 74.1M Q3 '22: 157M Q4 '22: 197.3M Q1 '23: 210.6M Q2 '23: 252.5M Q3 '23: 218.2M Q4 '23: 236.9M Q1 '24: 264.8M Q2 '24: 297.4M Q3 '24: 331.5M Q4 '24: 362.3M Q1 '25: 413M Q2 '25: 454.9M Q3 '25: 523.3M Q4 '25: 599.9M Q1 '26: 673.4M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q2 '21: -186M Q3 '21: -173.4M Q4 '21: -156.6M Q1 '22: -130.7M Q2 '22: -109.5M Q3 '22: -32.4M Q4 '22: 9.8M Q1 '23: 21.9M Q2 '23: 38.1M Q3 '23: -19.2M Q4 '23: -25.2M Q1 '24: -30.5M Q2 '24: -27.5M Q3 '24: -26.2M Q4 '24: -45.6M Q1 '25: -15.8M Q2 '25: 4.5M Q3 '25: 38.2M Q4 '25: 77.2M Q1 '26: 93.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q2 '21: -188.5M Q3 '21: -175.2M Q4 '21: -157.9M Q1 '22: -133.7M Q2 '22: -112.1M Q3 '22: 142.6M Q4 '22: 183.4M Q1 '23: 196.3M Q2 '23: 231.3M Q3 '23: -6.7M Q4 '23: 14.1M Q1 '24: 8.7M Q2 '24: -10.2M Q3 '24: -9.1M Q4 '24: -43.2M Q1 '25: -16.9M Q2 '25: 4.8M Q3 '25: 35.9M Q4 '25: 59M Q1 '26: 73.1M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue TTM

0 30M 60M 90M Q1 '22: 13.3M Q2 '22: 15.9M Q3 '22: 20.1M Q4 '22: 22.9M Q1 '23: 25.7M Q2 '23: 28.4M Q3 '23: 30.5M Q4 '23: 33.4M Q1 '24: 37M Q2 '24: 41.6M Q3 '24: 52.6M Q4 '24: 60.9M Q1 '25: 68.2M Q2 '25: 74.5M Q3 '25: 74.6M Q4 '25: 77.7M Q1 '26: 80.6M Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q2 '21: -154.4M Q3 '21: -148.6M Q4 '21: -126.3M Q1 '22: -123M Q2 '22: -92.1M Q3 '22: -1.5M Q4 '22: 5.8M Q1 '23: 38.4M Q2 '23: 42.5M Q3 '23: -2.6M Q4 '23: 13.3M Q1 '24: 21.6M Q2 '24: 30.5M Q3 '24: 11.2M Q4 '24: 25.7M Q1 '25: 44M Q2 '25: 66.9M Q3 '25: 102.9M Q4 '25: 138M Q1 '26: 165.9M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '19: -167.1M Q4 '19: -161.6M Q1 '20: -128.8M Q2 '20: -117.1M Q3 '20: -121.7M Q4 '20: -136.8M Q1 '21: -145M Q2 '21: -154.6M Q3 '21: -148.8M Q4 '21: -126.7M Q4 '23: 13.2M Q1 '24: 21.4M Q2 '24: 30.3M Q3 '24: 11.1M Q4 '24: 25.4M Q1 '25: 43.7M Q2 '25: 66.5M Q3 '25: 101.7M Q4 '25: 136.4M Q1 '26: 164.2M Q4 '19 Q3 '20 Q2 '21 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '21: 68.3M Q2 '21: 68.4M Q3 '21: 68.7M Q1 '22: 69.1M Q2 '22: 69.3M Q3 '22: 70.6M Q1 '23: 69.8M Q2 '23: 71.6M Q3 '23: 70.2M Q1 '24: 70.6M Q2 '24: 71M Q3 '24: 71.7M Q1 '25: 76.1M Q2 '25: 77.9M Q3 '25: 80M Q1 '26: 82.4M Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q2 '21: -2.80 Q3 '21: -2.58 Q4 '21: -2.29 Q1 '22: -1.93 Q2 '22: -1.61 Q3 '22: 2.01 Q4 '22: 2.58 Q1 '23: 2.76 Q2 '23: 3.26 Q3 '23: -0.12 Q4 '23: 0.19 Q1 '24: 0.12 Q2 '24: -0.15 Q3 '24: -0.13 Q4 '24: -0.61 Q1 '25: -0.25 Q2 '25: 0.04 Q3 '25: 0.45 Q4 '25: 0.75 Q1 '26: 0.91 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.